Ongoing clinical trials are evaluating a new immunotherapeutic approach for the treatment of malignant melanoma–the combination of an oncolytic virus with checkpoint inhibition.
Sigrid Eckardt, PhD
Advertisement
Articles by Sigrid Eckardt, PhD
Advertisement
Latest Updated Articles
Combining Oncolytic Immunotherapy With Checkpoint Inhibitors Could Affect CurePublished: November 21st 2014 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
4
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
5
